Related Experiment Video

Updated: May 30, 2026

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes
05:08

Plate-based Large-scale Cultivation of Caenorhabditis elegans: Sample Preparation for the Study of Metabolic Alterations in Diabetes

Published on: August 24, 2018

Inhibition of advanced glycation endproduct formation by foodstuffs

Chi-Hao Wu1, Shang-Ming Huang, Jer-An Lin

  • 1Department of Food Science and Biotechnology, National Chung-Hsing University, 250 Kuokuang Road, Taichung 40227, Taiwan.

Food & Function
|July 23, 2011
PubMed

Insights

The Maillard reaction, or glycation, forms toxic advanced glycation endproducts (AGEs) linked to aging and diabetes. This review explores natural food compounds that may inhibit AGEs, offering potential therapeutic benefits.

Area of Science:

  • Biochemistry
  • Gerontology
  • Diabetology

Background:

  • The Maillard reaction (glycation) generates advanced glycation endproducts (AGEs), implicated in aging and diabetic complications.
  • AGEs alter protein structure/function and trigger cellular damage via receptor interactions (RAGEs), leading to reactive oxygen species (ROS) and inflammation.
  • Current research focuses on AGEs' detrimental effects, with limited understanding of protective agents.

Purpose of the Study:

  • To review the anti-glycation properties of foodstuffs and their active components.
  • To discuss the mechanisms by which natural compounds inhibit AGE formation and related damage.
  • To explore therapeutic potential of natural AGE inhibitors for preventing aging and diabetic complications.

Main Methods:

  • Literature review of studies on glycation, AGEs, and phytochemicals.
  • Analysis of mechanisms underlying AGE inhibition by food components.
  • Synthesis of information on natural anti-AGE agents and their therapeutic implications.

Main Results:

  • Protein glycation leads to toxic AGEs, altering protein function and inducing cellular damage.
  • AGEs interact with RAGEs, promoting oxidative stress and inflammation.
  • Phytochemicals show potential protective effects against glycotoxin-induced damage.

Conclusions:

  • Natural compounds in foodstuffs may act as AGE inhibitors.
  • Investigating these natural agents offers a promising therapeutic strategy for age-related diseases and diabetes.
  • Further research into natural anti-AGE agents could lead to treatments with fewer adverse effects.

More Related Videos

Preparation of Naringenin Solution for In Vivo Application08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

Related Concept Videos

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Feedback Inhibition00:46

Feedback Inhibition

Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
Diabetic Neuropathy01:22

Diabetic Neuropathy

DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...